

1Breast Cancer Program, Istituto Europeo di Oncologia, Milano, Italy; 2Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA; 3Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria; 4Inklin St. Anna, Luzern, Switzerland; 5German Breast Group, Neu-Isenburg, Germany; 6Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA; 7Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; 8Tumor and Breast Center ZeTUP, St. Gallen; 9Breast Center, Kantonsspital St. Gallen, St. Gallen, Switzerland

Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017


10Institut de Cancérologie Gustave Roussy, Villejuif, France; 11Memorial Sloan Kettering Cancer Center, New York, USA; 12Karolinska Institute and University Hospital, Stockholm, Sweden; 13University of Bordeaux, Bordeaux, France; 14Universitäts-Frauenklinik Tübingen, Tübingen, Germany; 15Champalimaud Cancer Centre, Lisbon, Portugal; 16Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA; 17Hospital Universitario 12 de Octubre, Madrid, Spain; 18Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK; 19Institut für Pathologie, Charité-Universitätsmedizin Berlin, Berlin, Germany; 20Azienda Usl Toscana Centro, Prato, Italy; 21Righospitalet, Copenhagen, Denmark; 22Peter McCallum Cancer Centre, Melbourne, Australia; 23Kamara University School of Medicine, Istanbul, Turkey; 24University of Toronto, Mount Sinai Hospital, Toronto, Canada; 25University of Munich, München, Germany; 26Comprehensive Cancer Center, University of Michigan, Ann Arbor, USA; 27National Taiwan University Hospital, Taipei, Taiwan; 28University of Ulm, Ulm, Germany; 29The National Cancer Institute, Cairo University, Cairo, Egypt; 30Medical University of Gdansk, Gdansk, Poland; 31Hospital Affiliated to Military Medical Science, Beijing, China; 32Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrens University Hospital, Gothenburg, Sweden; 33Baylor College of Medicine, Houston, USA; 34Institute of Oncology Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland; 35Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Canada; 36National Cancer Center, Ilsan-dong-gu, Goyang-si, Gyeonggi-do, Korea; 37Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; 38KH Salzburg, Paracelsus Medical University Clinics, Salzburg, Austria; 39N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; 40Fudan University Cancer Hospital, Shanghai, China; 41The Royal Marsden, Sutton, Surrey, UK; 42Graduate School of Medicine Kyoto University, Saiyo-ku, Kyoto City, Japan; 43Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK; 44University of Milan, Milan; 45Istituto Europeo di Oncologia, Milano, Italy; 46Hamamatsu Oncology Center, Hamamatsu, Japan; 47McMaster University, Hamilton, Canada; 48National Cancer Center, Chaoyang District, Beijing, China

*Correspondence to: Prof. Giuseppe Curigliano, Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milano, Italy. Tel: +39-02-57-48-94-39; Fax: +39-02-94-37-92-24; E-mail: giuseppe.curigliano@ieo.it

Both authors contributed equally as senior authors.

© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
The 15th St. Gallen International Breast Cancer Consensus Conference was held in March 2017 in Vienna, Austria. This meeting is a global, multidisciplinary conference with representatives from 160 nations and every continent. The highlight of the conference is the consensus panel, in which 52 panelists review and discuss specific areas of treatment with a focus on controversies in the management of early-stage breast cancer. The goal of this consensus process is to articulate important themes in management, and to provide guidance to clinicians around the world on how to think about and care for women with early-stage breast cancer. It is acknowledged that not all countries have equal access to therapeutic and diagnostic resources. In light of that, the Panel attempts to review less costly alternatives when they may be appropriately utilized (Table 1).

The theme for this year’s conference was to focus on areas of ‘escalation’ or ‘de-escalation’. That is—to identify areas where optimal care may be achieved with ‘less’ or ‘more’ treatment. The Panelists believe very strongly in the importance of evidence-based clinical care. At the same time, they recognize that data from randomized phase III studies are not always relevant to specific situations and may not be available to resolve important clinical decisions. The needs of a specific patient may be better defined through consideration of subset analyses or other individualized approaches to care. In these instances, the Panel voiced its expert judgment in order to assist in the care of individual women as best they could. The Panel endorses treatment in well-designed clinical trials allowing access to best available care.

**Ductal carcinoma in situ**

Breast conserving surgery followed by radiation therapy remains the standard of care for ductal carcinoma *in situ* (DCIS) [1, 2] assuming adequate margins can be obtained. The majority of panel endorsed recent Surgical Society of Oncology (SSO), American Society of Clinical Oncology (ASCO) and American Society for Radiation Oncology (ASTRO) guidelines that recommended that a margin ≥2 mm is sufficient to avoid recurrence [3]. A substantial minority of the panel would accept narrower margins in individual cases, including ‘no ink on DCIS’. The Panel acknowledged the recent trials showing that either aromatase inhibitors (AIs) or tamoxifen can be an effective adjuvant treatment options to lower the risk of recurrent DCIS [4, 5].

**Primary surgery for early breast cancer**

The Panel discussed whether women with multifocal (multiple areas of tumor in one quadrant) or multicentric (multiple areas of tumor affecting more than one quadrant) are candidates for breast conservation. The Panel strongly endorsed breast conservation for both multifocal and multicentric disease provided that surgical margins are negative, that radiotherapy is anticipated, and that the surgical resection would achieve adequate cosmesis. The Panel reiterated the ‘no ink on tumor’ rule for surgical margins of invasive breast cancer, and recommended this standard regardless of tumor biology or subtype [6].

A meta-analysis of single-center experiences suggests very low risk of local-regional recurrence following nipple-sparing mastectomy [7]. Based on these observations, the Panel endorsed nipple-sparing mastectomy as an appropriate surgical option. Additionally, the Panel specifically endorsed nipple-sparing mastectomy as an option for breast surgery in women with known hereditary BRCA1/2 mutations provided that there was careful review of the retro-areolar tissue by pathology with no evidence for tumor in that region.

Based on the American College of Surgeons Oncology Group (ACOSOG) Z-11 trial, it has become standard to avoid axillary dissection in women with 1 or 2 positive sentinel lymph nodes who have had breast conservation and will be receiving whole breast radiation and adjuvant systemic therapy, regardless of tumor biology [8]. The Panel believed that either standard ‘tangents’ or ‘high tangents’ were appropriate radiation fields for such cases, and had no specific preference.

The Panel discussed how this experience relates to women who have had mastectomy. The Panel recommended additional therapy to the axilla in women who had had mastectomy and sentinel
## Table 1. Research recent findings and clinical implications

<table>
<thead>
<tr>
<th>Field of treatment</th>
<th>Findings and implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetics</td>
<td>Multi-gene panel testing for hereditary breast cancer becomes widespread, frequently identifying deleterious mutations in women with family history but negative BRCA1/2 testing, and also introducing substantial numbers of variants of unknown significance [46].</td>
</tr>
<tr>
<td>Surgery of ductal carcinoma in situ</td>
<td>Meta-analysis and expert panel recommends ≥2 mm margins as optimal for women receiving breast conserving surgery and radiation therapy for DCIS [3].</td>
</tr>
<tr>
<td>Systemic therapy of ductal carcinoma in situ (DCIS)</td>
<td>Randomized trials comparing the aromatase inhibitor (AI), anastrozole, against tamoxifen as treatment of estrogen receptor (ER) positive DCIS showed that the AI was at least as effective as tamoxifen, with differences in side-effect profiles [4, 5].</td>
</tr>
<tr>
<td>Surgery of the axilla after neoadjuvant therapy</td>
<td>Prospective trials of sentinel node vs axillary node dissection for women with node-positive breast cancer following neoadjuvant chemotherapy showed that false-negative rates for sentinel lymph node (SLN) were in excess of 10%. However, the SLN mapping may be acceptable in selected cohorts [11–13].</td>
</tr>
<tr>
<td>Partial breast irradiation</td>
<td>In a randomized trial of low-risk patients with early breast cancer who received breast conserving surgery, accelerated partial breast irradiation was not inferior to standard whole breast irradiation [47].</td>
</tr>
<tr>
<td>Regional nodal irradiation</td>
<td>Randomized trials demonstrate reduced local-regional and distant metastatic recurrence, with emerging survival advantage, for regional nodal irradiation to supraclavicular, axillary and internal mammary lymph nodes when treating high-risk breast cancers following breast surgery. While reducing risk of recurrence, regional nodal irradiation was associated with greater risk of toxicity and may complicate reconstructive surgery [20, 21].</td>
</tr>
<tr>
<td>Neoadjuvant therapy—Chemotherapy</td>
<td>The inclusion of carboplatin with anthracycline- and taxane-based chemotherapy improved the rate of pathologic complete response (pCR) in triple negative breast cancer (TNBC) and translated into disease-free survival benefit though the role for such treatment when patients additionally receive standard alkylator therapy is less clear [48]. In an adaptive randomized trial, the addition of carboplatin and the PARP inhibitor, veliparib, improved the rate of pCR in TNBC [49]. There were inconsistent findings for the use of nab-paclitaxel instead of paclitaxel as neoadjuvant chemotherapy [50, 51].</td>
</tr>
<tr>
<td>Neoadjuvant therapy—HER2 targeted therapy</td>
<td>Long-term follow-up of NeoSphere trial suggests disease-free survival advantage parallels increased rate of pCR with pertuzumab- and trastuzumab-based therapy [52]. The antibody–drug conjugate, ado-trastuzumab emtansine paired with pertuzumab was less effective at achieving pCR than the chemotherapy–trastuzumab–pertuzumab TCHP [53]. An adaptive randomized trial suggested that the dual tyrosine kinase inhibitor neratinib, might improve rates of pCR compared with trastuzumab-based regimens though this awaits confirmation [54].</td>
</tr>
<tr>
<td>Neoadjuvant therapy—endocrine therapy.</td>
<td>The addition of the cyclin-dependent kinase (CDK) 4/6 inhibitors to aromatase inhibitor treatment dramatically suppresses tumor cell proliferation [55–57]. Among women with low genomic scores, neoadjuvant endocrine therapy is associated with high rates of clinical response [58].</td>
</tr>
<tr>
<td>Post-neoadjuvant therapy—clinical trials</td>
<td>Ongoing trials are evaluating post-neoadjuvant therapy for patients who have residual cancer. Agents under investigation include CDK 4/6 inhibitors, poly ADP ribose polymerase (PARP) inhibitors, platinum agents, ado-trastuzumab emtansine, immunotherapy agents, and others. Adjuvant capecitabine may reduce recurrence in women with residual cancer after neoadjuvant chemotherapy [42].</td>
</tr>
<tr>
<td>Adjuvant therapy—Chemotherapy</td>
<td>The ABC trials suggest that inclusion of anthracylines in addition to taxanes and alkylator chemotherapy remains valuable for triple-negative and stage II/III ER positive cancers treated with adjuvant chemotherapy [59]. The addition of bevacizumab to chemotherapy did not improve long-term outcomes for triple-negative breast cancer [60]. Adjuvant capecitabine may reduce recurrence in TNBC when added to anthracycline- and taxane-based chemotherapy [61], and may reduce recurrence in women with residual cancer after neoadjuvant chemotherapy [42]. ‘Dose-dense’ chemotherapy scheduling is validated for reducing cancer recurrence while 5-fluorouracil was shown to not affect recurrence risk [62, 63].</td>
</tr>
<tr>
<td>Adjuvant therapy—HER2 targeted therapy</td>
<td>Despite multiple trials demonstrating enhanced rates of pCR with the addition of lapatinib to trastuzumab-based neoadjuvant chemotherapy, long-term findings from the ALTTO study do not suggest reduced recurrence risk with adjuvant lapatinib [64]. The ExtaNet study suggests that extended anti-HER2 treatment with the dual tyrosine kinase inhibitor, neratinib, reduces recurrence risk, particularly in ER positive, HER2 positive tumors but is associated with significant rates of diarrhea [65]. Trastuzumab reduced risk even in small, sub-centimeter, node-negative breast cancers [66]. Paclitaxel and trastuzumab is an effective regimen for stage I breast cancers with low rates of recurrence [67]. Dual blockade with pertuzumab and trastuzumab improves outcome among patients who are at higher risk for relapse because of lymph-node involvement or hormone-receptor negativity [90].</td>
</tr>
<tr>
<td>Adjuvant therapy—endocrine therapy</td>
<td>In premenopausal women with ER positive breast cancer, ovarian suppression reduces recurrence in high-risk tumors but is associated with more menopausal symptoms [32, 68]. In postmenopausal women, multiple trials have studied extended endocrine therapy with an aromatase inhibitor and have shown reduced rates of breast cancer events, including distant recurrence and contralateral breast cancers though the absolute benefit is modest [38, 41]. Randomized trials show equivalence between anastrozole and letrozole as adjuvant treatment [69].</td>
</tr>
<tr>
<td>Gene expression profiling for early-stage breast cancer: prospective studies</td>
<td>In the MINDACT trial, a 70-gene signature paired with clinical risk criteria identified patients with breast cancer who did not derive substantial benefit from adjuvant chemotherapy [23]. In the TAILORx and West German Plan B trials, a very low 21-gene recurrence score identified a cohort of patients with ER positive breast cancer and an excellent prognosis with endocrine therapy alone [24, 25].</td>
</tr>
</tbody>
</table>

Continued
Neoadjuvant therapy serves two main goals. It provides effective systemic treatment (equivalent to adjuvant therapy) to prevent cancer recurrence, and allows de-escalating surgery for many women with larger tumors and/or axillary nodal involvement. The Panel addressed the question: ‘Should the entire area of the original primary be resected after neoadjuvant therapy or should the resection include only the residual area of tumor?’; and the panel deliberated about the appropriate surgical margins following neoadjuvant therapy [9]. The Panel recommended that the extent of residual tumor guide the extent of breast surgery, and that full resection of the initial tumor bed was not necessary. In general, the Panel favored the ‘no ink on tumor’ standard for surgical margins following neoadjuvant therapy. However, in cases of multifocal residual disease and/or cases of ‘scattered’ residual disease, many panelists expressed an expert opinion to favor more ‘generous’ margins. No single standard of care exists and the multidisciplinary team caring for the patient needs to exercise appropriate clinical judgment. Similarly, the Panel agreed that nipple-sparing mastectomy was an option for patients following neoadjuvant treatment provided the retro-areolar region lacked tumor involvement [10].

### Axillary surgery following neoadjuvant therapy

The Panel deliberated on appropriate axillary surgery following neoadjuvant chemotherapy. In a woman who presented with a clinically negative axilla and who received neoadjuvant treatment, the Panel strongly believed sentinel node biopsy to be appropriate and favored the biopsy be carried out after neoadjuvant treatment.

There was more controversy regarding sentinel node surgery for women who presented with a clinically positive axilla, and had a clinical response with down staging to a clinically negative axilla. The Panel believed sentinel node biopsy, as opposed to axillary dissection, to be adequate if at least three or more negative sentinel nodes were detected and examined [11–14]. Because of concerns for false-negative results with limited sampling, sentinel node surgery was generally considered not adequate if only one or two negative sentinel nodes were identified. The Panel recommended that patients with a clinically positive axilla or with macro-metastases identified in sentinel nodes after neoadjuvant therapy undergo completion axillary dissection [15]. The Panel was split on whether residual micro-metastatic lymph node involvement warranted completion dissection after neoadjuvant therapy.

### Radiation therapy after breast surgery

Because of high levels of evidence for safety and long-term efficacy, the Panel believed hypo-fractionated treatment was an appropriate standard for the majority of patients, particularly those over age 50 years, and that this represented an opportunity for...
treatment de-escalation [16]. The Panel also recognized partial breast irradiation as an option for women meeting the low-risk criteria put forward by the ASTRO/European Society for Radiotherapy and Oncology (ESTRO) guideline though acknowledged that there was less evidence for this approach [17]. For women with intermediate or higher clinical risk, the Panel preferred whole breast irradiation. In another instance of de-escalation, the Panel believed that ‘boost’ could be omitted in patients aged ≥60, with low grade tumor features and/or favorable tumor biology who will be taking adjuvant endocrine therapy [18, 19].

Two recent randomized trials have shown improved oncological outcomes in terms of disease free survival for regional nodal irradiation (RNI) for women with higher risk breast cancers [20, 21]. The Panel recommended RNI in patients with pN1 (one to three positive nodes) cancers and adverse clinical features including young age (≤40 years), adverse biology such as low or negative estrogen receptor (ER) expression, high grade features, and extensive lympho-vascular invasion (LVI), and all patients with four or more positive lymph nodes. For women pN1 with lower risk features the potential benefits of RNI should be weighed against risks for toxicity, including pneumonitis and lymphedema. The Panel recommended post-mastectomy radiation therapy (PMRT) in all patients with four or more positive lymph nodes and/or T3 tumors. For pN1 with lower risk features the use of PMRT should be weighed against risks for toxicity, including increased of complications following breast reconstruction.

Table 2 summarizes treatment recommendations for loco-regional therapies.

The Panel acknowledged the limited data for tailored radiation therapy based on neoadjuvant treatment response, and recommended that both baseline and post-treatment cancer stage be considered in planning whether and how to administer radiation therapy. Finally, in the sentinel node-era, it is likely that radiation treatment decisions will need to be made with less complete staging information. Ongoing clinical trials including the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-51 and Alliance A11202 studies will inform this decision.

**Characterization of tumor biology, subtypes, and genomic signatures**

The St. Gallen Consensus has for years led in the development of treatment tailored toward clinical and biological subsets of breast cancer. In broad clinical terms, there are four subtypes of breast cancer that call for distinct treatment approaches: triple-negative tumors, for which chemotherapy is both effective and the only available therapy; HER2 positive tumors regardless of ER status, for which anti-HER2 therapy and chemotherapy are indicated; and two types of ER positive breast cancer, both of which are treated with endocrine therapy. For many of these patients with hormone receptor positive disease, chemotherapy can be omitted. ER and progesterone receptor (PR) status is determined by immunohistochemistry (IHC); human epidermal growth factor receptor (HER2) status is determined by IHC and/or in situ hybridization assays. In addition, tumors are characterized by grade and proliferative fraction (most commonly assessed by Ki-67 immunostaining), factors that may affect the recommendation for chemotherapy in ER positive tumors (Table 3). The Panel raised an issue of caution about reproducibility of IHC for Ki67 and its use to make clinical decisions, due to the variability of this assay. If used, panelists suggested to calibrate a common scoring method in order to achieve high inter-laboratory reproducibility in Ki67 scoring on centrally stained tissue microarray slides [88, 89]. Although these data are potentially encouraging, suggesting that it may be possible to standardize scoring of Ki67 among pathology laboratories, clinically important discrepancies persist. The Panel recommended against routine reporting of tumor infiltrating lymphocytes for early breast cancer.

As a clinical ‘short-hand’, tumors are often classified as ‘luminal-A like’ or ‘luminal-B like’ based on routine pathology. Luminal A-like tumors are typically low grade, strongly ER/PR positive, HER2 negative and have low proliferative fraction. Luminal-B-like tumors are ER positive but may have variable degrees of ER/PR expression, are higher grade, and have higher proliferative fraction. The Panel acknowledged that these classifications based on routine histopathology were clinically valuable, and could be used to inform adjuvant treatment decisions. Specifically, the panel agreed that either grading or Ki-67 could be used to distinguish between the Luminal—A and B-like (Table 3).

However, the panel agreed that, when available, gene expression signatures were preferable to standard pathology, when adequate reproducibility is not granted. There was considerable discussion concerning the indication for gene expression signatures [22]. The panel agreed that there was no role in clinical low risk cases [such as pT1a/b, grade 1 (G1), ER high, N0] and similar settings where chemotherapy would not be indicated under any circumstances. The Panel agreed that a number of gene expression signatures served as prognostic markers in the setting of adjuvant endocrine therapy in node-negative breast cancers, including the 21 gene recurrence score, the 70 gene signature, the PAM50 ROR score®, the EpiClin score®, and the Breast Cancer Index®. The Panel endorsed all of these assays for guiding the decision on adjuvant chemotherapy in node-negative tumors as they all identify node-negative cases at low risk, with an excellent prognosis that would not warrant chemotherapy [23–27].

Nodal status is a strong prognostic factor regardless of gene expression signature. The Panel agreed that gene expression signatures offered information that can refine the prognosis for node-positive breast cancers. However, the Panel did not uniformly endorse the use of gene expression signatures for making treatment decisions regarding adjuvant chemotherapy in node-positive cases. The 21-gene recurrence score and the 70-gene signature have now been evaluated in prospective studies including small numbers of node-positive cancers. In the prospective trial (MINDACT), only patients with node-negative, or one to three positive nodes were included. Patients with low-risk tumor scores and a limited degree of nodal involvement appear to have a good prognosis with or without chemotherapy [28, 29].

The Panel reviewed similar data showing that some gene expression signatures appear to be prognostic for late recurrence of ER positive breast cancers after 5 years of adjuvant endocrine therapy [30, 31]. However, the Panel did not recommend the use of gene expression signatures for choosing whether to recommend extended adjuvant endocrine treatment, as no prospective data exist and the retrospective data were not considered sufficient to justify the routine use of genomic assays in this setting.
### Table 2. Treatment recommendations for loco-regional therapy

<table>
<thead>
<tr>
<th>Local therapy</th>
<th>Theme</th>
<th>De-escalation</th>
<th>Escalation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary surgery: invasive breast cancer</td>
<td>Margins</td>
<td>Re-excision and mastectomies can be avoided with margins no larger than no tumor on ink</td>
<td>Re-excision for larger margins discouraged including cases with aggressive biology</td>
</tr>
<tr>
<td></td>
<td>Multifocal and multicentric disease</td>
<td>Breast conservation if margins clear and RT anticipated</td>
<td>Mastectomy in other cases</td>
</tr>
<tr>
<td>Surgery for DCIS</td>
<td>Margins</td>
<td>2 mm margins sufficient to avoid second surgery</td>
<td>Re-excision for larger margins discouraged</td>
</tr>
<tr>
<td>Surgery after neoadjuvant chemotherapy in case of downstaging in breast and axilla</td>
<td>Surgery of the breast</td>
<td>Resection of residual disease and not original tumor area</td>
<td>Resection of the original tumor area in cases of refractory disease</td>
</tr>
<tr>
<td></td>
<td>Margins</td>
<td>No tumor on ink in concentric shrinkage/unifocal residual disease</td>
<td>Consider re-excision (2 mm margins) in multifocal residual disease/‘scattered’ remission</td>
</tr>
<tr>
<td>Sentinel lymph node biopsy in cN (−) at diagnosis</td>
<td>Appropriate in most cases</td>
<td>Auxillary dissection if sentinel lymph node metastasis detected</td>
<td></td>
</tr>
<tr>
<td>Sentinel lymph node biopsy in cN (+) at diagnosis</td>
<td>Appropriate only if three or more lymph nodes detected as sentinels</td>
<td>Auxillary dissection in most cases outside of clinical trials</td>
<td></td>
</tr>
<tr>
<td>Radiotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypofractionation</td>
<td>Strong recommendation for ages ≥ 50 and node negative</td>
<td>Consider standard radiotherapy regimens for all others</td>
<td></td>
</tr>
<tr>
<td>Partial breast irradiation</td>
<td>Consider for ASTRO/ESTRO low risk group, especially when receiving adjuvant endocrine therapy</td>
<td>Consider whole breast irradiation for all others</td>
<td></td>
</tr>
<tr>
<td>Boost</td>
<td>Omit boost in patients ≥ 60 years, low grade, or favorable biological profile</td>
<td>Consider boost in other patients</td>
<td></td>
</tr>
<tr>
<td>Post-mastectomy radiation therapy (PMRT)</td>
<td>Consider omitting radiotherapy in women with pT1–pT2, N1 (1–3), and favorable biological profile</td>
<td>PMRT in patients with pT3 or four or more positive lymph nodes</td>
<td></td>
</tr>
<tr>
<td>Regional nodal irradiation (RNI)</td>
<td>Consider omitting RNI in N1 (1–3 positive lymph nodes) in the absence of adverse clinical factors</td>
<td>RNI in N1 cancers and adverse clinical features (≤ 40 years, low or negative estrogen receptor (ER), G3, extensive lympho-vascular invasion) or &gt; 3 positive nodes</td>
<td></td>
</tr>
</tbody>
</table>

### Table 3. Definition of subtypes

<table>
<thead>
<tr>
<th>Clinical grouping</th>
<th>Notes&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triple negative</td>
<td>Negative ER, PR and HER2</td>
</tr>
<tr>
<td>Hormone receptor-negative and HER2-positive</td>
<td>ASCO/CAP guidelines</td>
</tr>
<tr>
<td>Hormone receptor-positive and HER2-positive</td>
<td>ASCO/CAP guidelines</td>
</tr>
<tr>
<td>Hormone receptor-positive and HER2-negative – a spectrum of ER+/HER2-negative</td>
<td>ER and/or PgR positive ≥ 1%</td>
</tr>
<tr>
<td>High receptor, low proliferation, low grade (luminal A-like)</td>
<td>Multi-parameter molecular marker ‘good’ if available&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Intermediate</td>
<td>High ER/PR and clearly low Ki-67 or grade.</td>
</tr>
<tr>
<td>Low receptor, high proliferation, high grade (luminal B-like)</td>
<td>Multi-parameter molecular marker ‘intermediate’ if available.</td>
</tr>
</tbody>
</table>

<sup>a</sup>Basal like breast cancer and HER2-enriched subtype can be defined by genomic assay only.

<sup>b</sup>No role for gene testing in clinical pathologic low risk cases (pT1a, pT1b, G1, ER high, pN0).
The Panel discussed the routine indications for multigene testing in ER positive breast cancer. The principal role is to recommend for or against adjuvant chemotherapy. In patients who are not candidates for adjuvant chemotherapy owing to comorbid health conditions or tumor stage/risk, or in patients who ‘obviously’ need adjuvant chemotherapy, typically including stage III breast cancer, there is no routine need for genomic tests. In general, the zone ‘in between’ is where genomic assays may be most valuable. These would often be patients with tumors between 1 and 3 cm, with zero to two or three positive lymph nodes, and intermediate proliferative fraction. Multigene assay should not be the only factor considered in making a decision to proceed or to avoid chemotherapy. This broad description is intended to give guidance to clinicians and was not intended to deny access of patients with other clinical presentation where the refined prognosis available by genomic assay might reasonably inform the adjuvant chemotherapy decision.

**Adjuvant endocrine therapy: premenopausal women**

Tamoxifen is the historical standard adjuvant endocrine therapy for premenopausal women. The Panel reviewed data from recent trials of adjuvant ovarian function suppression (OFS) that demonstrated that OFS can lower the risk of breast cancer recurrence in higher risk cancers [32]. The Panel identified age ≤35 and/or involvement of 4 or more lymph nodes as factors arguing for inclusion of OFS. In general, based on published reports, women with sufficient tumor risk so as to warrant chemotherapy may wish to consider OFS. The Panel believed OFS could be paired with either tamoxifen or an AI (Table 4) [33, 34]. Chemotherapy may cause transient or permanent menopause in younger women. The Panel urged caution when interpreting laboratory assays of pituitary—ovarian function such as estradiol, follicle-stimulating hormone, or luteinizing hormone levels in women treated with chemotherapy, and encouraged use of gonadotropin-releasing hormone (GnRH) agonist therapy to achieve OFS when there was any clinical ambiguity regarding menstrual function, particularly if an AI is administered (Table 4).

**Adjuvant endocrine therapy: postmenopausal women**

A vast literature supports the use of tamoxifen or AIs in the adjuvant treatment of postmenopausal women. Large randomized trials have shown that initial treatment with AIs may reduce recurrence risk and improve survival compared with tamoxifen alone. The Panel noted that tamoxifen alone is still appropriate for some patients. Slightly more than half of the panelists believed that an AI should be used at some point during the course of adjuvant therapy. Factors that favored the use of an AI include node positivity, high Ki67, high grade, lobular histology, and HER2 positivity. In women at high risk of recurrence, the panel favored the use of an AI as initial therapy. The Panel acknowledge that the importance of patient preference and tolerability of therapy, particularly given the modest differences between tamoxifen and AIs even in somewhat high-risk patients (Table 4) [36, 37].

Over the past decade, multiple trials have examined the role of extended adjuvant endocrine therapy beyond 5 years of treatment. Options include extended tamoxifen to 10 years, extended AI therapy to 10 years, or 5 years of tamoxifen and then switching to an AI. The benefits of extended therapy include reductions in risk of loco-regional and distant recurrence and in contralateral breast cancer. The Panel deliberated on which women should receive longer durations of therapy. In general, the Panel recommended longer durations in women with moderate to high risk of recurrence, typically defined as stage II or III breast cancer. In women with stage I cancers, the Panel favored only 5 years of treatment (Table 4). Based on data from recently presented studies, the Panel was more inclined to recommend extended therapy in women who had received tamoxifen as initial therapy, and in women where secondary prevention was an important treatment goal [38–41]. The Panel underscored the importance of patient preference and tolerability in this treatment decision, as extended therapy is associated with ongoing menopausal symptoms and risks to bone health, and yields only modest benefits in terms of preventing breast cancer recurrence, especially in patients who have completed 5 years of AI therapy (Table 4).

The Panel recommended that premenopausal women who are at high risk for recurrence and have concluded 5 years of tamoxifen should extend endocrine therapy for up to 10 years (Table 4) [35].

**Which patients should receive adjuvant chemotherapy?**

**Triple-negative breast cancer**

The Panel recommended adjuvant chemotherapy for triple-negative breast cancer (TNBC) stage T1b pN0 and higher; the majority recommended against routine adjuvant chemotherapy for pT1a pN0 TNBC (Table 4). The Panel preferred anthracycline- and taxane-based chemotherapy for most patients, but particularly for those with stage II and III disease. The Panel clearly recommended against routine use of platinum-based chemotherapy in unselected TNBC cases. In BRCA1/2 associated cancers, the Panel was evenly split on whether to recommend adjuvant platinum chemotherapy though agreed that such patients should receive alkylating chemotherapy in addition to a taxane and anthracycline. Acceptable regimens included dose-dense and non-dose-dense anthracycline-, taxane-, and alkylator chemotherapy schedules (Table 5).

**HER2 positive breast cancer**

The Panel recommended adjuvant chemotherapy and anti-HER2 therapy for HER2 positive, stage pT1b pN0 and higher breast cancers; it recommended against routine adjuvant chemotherapy and anti-HER2 therapy for pT1a pN0 HER2 positive breast cancers. The Panel believed that the paclitaxel–trastuzumab regimen was sufficient for most stage 1, HER2 positive cancer but recommended anti-HER2 therapy be paired with additional chemotherapy agents for stage II or III cancer (Table 5).
Table 4. (Neo)-Adjuvant systemic treatment recommendations for ER positive/HER2 negative early breast cancer

<table>
<thead>
<tr>
<th>Subtypes according to clinical-pathological and genomic risk assessment</th>
<th>Treatment recommendation</th>
<th>De-escalation</th>
<th>Escalation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ER positive &amp; HER2-negative</strong></td>
<td>Endocrine therapy alone according to menopausal status</td>
<td>No role for extended adjuvant tamoxifen beyond 5 years</td>
<td>No OFS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Premenopausal</th>
<th>Postmenopausal</th>
</tr>
</thead>
<tbody>
<tr>
<td>High receptor, low tumour burden (pT1a, pT1b), no nodal involvement (pN0), low proliferation, low grade or low “genomic risk”</td>
<td>Tamoxifen 5 years</td>
<td>Tamoxifen or AI for 5 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The majority of the panel recommended against extended adjuvant endocrine therapy beyond 5 years</td>
</tr>
</tbody>
</table>

| High/Intermediate degree of ER and PgR expression, intermediate tumour burden pT1c, pT2, pN0 or pN1 (1-3), intermediate or high proliferation or grade, and/or intermediate “genomic risk” | Endocrine therapy according to menopausal status plus adjuvant chemotherapy |

<table>
<thead>
<tr>
<th></th>
<th>Premenopausal</th>
<th>Postmenopausal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncertain “clinical risk” (node negative) “intermediate genomic risk”</td>
<td>OFS plus tamoxifen or OFS plus exemestane</td>
<td>Consider addition of chemotherapy in selected cases</td>
</tr>
<tr>
<td>Premenopausal intermediate/high “clinical risk” (node positive) “Intermediate/high genomic risk”</td>
<td>OFS plus exemestane plus adjuvant chemotherapy in many cases</td>
<td>Extended adjuvant endocrine therapy with tamoxifen in some cases</td>
</tr>
<tr>
<td>Post-menopausal</td>
<td>Al up front</td>
<td>Chemotherapy</td>
</tr>
<tr>
<td>Uncertain “clinical risk” (node negative) “intermediate genomic risk” Postmenopausal “Intermediate/high genomic risk” and intermediate/high “clinical risk” (node positive)</td>
<td>Chemotherapy</td>
<td>Extended adjuvant endocrine therapy with tamoxifen</td>
</tr>
<tr>
<td>Intermediate to low ER and PR expression Higher tumor burden (typically T3 and/or N2-3 More proliferative / higher Ki67 “Intermediate to high genomic risk markers”</td>
<td>Adjuvant chemotherapy plus endocrine therapy according to menopausal status</td>
<td>Bisphosphonates</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Premenopausal high risk</th>
<th>Postmenopausal high risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjuvant chemotherapy and OFS + AI (if premenopausal after chemo)</td>
<td>Adjuvant chemotherapy and AI</td>
<td>Extended adjuvant AI according to risk and tolerability</td>
</tr>
</tbody>
</table>

Denosumab has been shown to reduce bone-health related events in breast cancer patients

---

Intermediate to low ER and PR expression

Higher tumor burden (typically T3 and/or N2-3)

More proliferative / higher Ki67

“Intermediate to high genomic risk markers”

Premenopausal high risk

Adjuvant chemotherapy and OFS + AI (if premenopausal after chemo)

Extended adjuvant AI according to risk and tolerability

Bisphosphonates

Denosumab has been shown to reduce bone-health related events in breast cancer patients
The Panel recommended a duration of 1 year of adjuvant trastuzumab alone, based on current evidence (Table 5). At the time of the Consensus Conference data of APHINITY trial were not available. In women who received neoadjuvant anti-HER2 therapy with dual blockade pertuzumab and trastuzumab, the Panel recommended completion of one year of trastuzumab alone but did not recommend adjuvant pertuzumab based on current evidence. The Panel did not address the question on dual blockade in the adjuvant setting since data on APHINITY trial were not available. The Panel did not answer the question on dual blockade in the neoadjuvant setting.

The majority of the Panel endorsed adjuvant use of adequately evaluated biosimilar trastuzumab, according to the criteria of extrapolation defined between regulatory agencies.

There is evidence from a single randomized trial that extended adjuvant therapy with neratinib after 1 year of trastuzumab may reduce recurrence in HER2 positive breast cancer, particularly in ER positive, HER2 positive cancers. The Panel did not specifically address the role of this agent pending further study (Table 5).

**ER positive, HER2 negative breast cancer**

Treatment decisions for chemotherapy in ER positive breast cancers can be guided by either IHC/pathology or by gene expression signatures. The Panel identified traditional pathology factors as relative indications for adjuvant chemotherapy including node-positive stage, extensive LVI, high Ki-67, and low hormone-receptor expression. The role of young age, per se, as an indication for chemotherapy was less strongly endorsed given the growing appreciation for tumor biology as the determinant of outcome and the potential role for ovarian suppression.

The Panel recommended against adjuvant chemotherapy in women with stage 1 or 2, luminal-A-like cancers (strongly ER and PR positive, HER2 negative, with low grade and proliferation markers), especially when genomic assays predicted the lack of benefit for chemotherapy treatment. The Panel recommended against adjuvant chemotherapy in women with luminal-B-like tumors with low genomic risk scores on the 21- or 70-gene signatures, when presenting with limited nodal involvement [23–25]. Some of the panelists urged caution about withholding adjuvant chemotherapy in node positive patients until more gene expression data in women treated with and without chemotherapy are available that will allow to safely de-escalate treatment in the ER+/HER2 negative, N1-3 subset. In cases of intermediate genomic scores or greater, the Panel recommended chemotherapy in...
luminal-B-like and/or node-positive cancers. The Panel preferred standard anthracycline- and taxane-based chemotherapy for most patients with ER positive breast cancer warranting chemotherapy.

**Neoadjuvant therapy and post-neoadjuvant therapy**

The Panel strongly endorsed the use of neoadjuvant therapy for stage II or III, HER2 positive or triple-negative breast cancer as the preferred initial treatment approach, particularly when there is any suggestion that additional therapy might enable disease control or survival benefit. For HER2 positive cancers, the Panel endorsed dual anti-HER2 neoadjuvant therapy with pertuzumab and trastuzumab with chemotherapy as a commonly administered option. For triple-negative cancers, the Panel recommended similar approaches to those that would be used in adjuvant therapy (Table 5).

Patients with residual cancer after neoadjuvant chemotherapy are at greater risk for recurrence than those who achieve complete pathologic response. At this juncture, there are no published data that additional therapy—beyond `standard’ treatment—reduces recurrence risk in women with residual disease [42]. The Panel was ambivalent about the role of additional therapy in the post-neoadjuvant setting, and there was no consensus on whether additional therapy should routinely be added, or which treatment might be preferred. A recent trial used capcitabine in this setting with very encouraging results, but the panelists noted the absence of confirmatory data and the historical lack of substantial benefit for adjuvant capcitabine. Ongoing clinical trials are evaluating the role of therapeutic escalation with various treatments including additional chemotherapies, targeted agents, anti-HER2 therapies, PARP inhibitors, and immune checkpoint inhibitors in this setting.

**Adjuvant use of bone modifying therapy**

Based on a meta-analysis of multiple trials, the Panel strongly endorsed the use of bisphosphonates as adjuvant treatment of postmenopausal women with breast cancer [43, 87]. Preferred regimens include zoledronic acid every 6 months for 5 years, or weekly oral clodronate for 3 years. The Panel recommended against such treatments for premenopausal women who are continuing to have regular menstrual cycles. However, a majority of the Panel favored this option for premenopausal women receiving OFS. Denosumab has been shown to reduce bone-health related events in breast cancer patients and may reduce recurrence but only a minority of panelists favored the option of substituting denosumab for bisphosphonates [43, 44].

**Survivorship and quality of life**

The Panel endorsed scalp cooling devices to reduce the likelihood of alopecia related to neo/adjuvant chemotherapy with non-anthracycline regimens [45].

The Panel endorsed lifestyle, diet, and weight management strategies appropriate to the general population, acknowledging that there are as yet no data that specific diet, lifestyle, or weight interventions affect the risk of breast cancer recurrence.

**Considerations in special populations**

**Elderly patients**

The Panel resolutely endorsed the statement that there is no absolute age limit for adjuvant chemotherapy but rather the recommendation should depend on the health status of the patient, the risk of cancer recurrence, the likely benefit of therapy, and patient preferences. The Panel acknowledged that many older patients (greater than 65 years) with ER positive, HER2 negative, low clinical and/or genomic risk and taking adjuvant endocrine therapy could omit radiation therapy after breast conserving surgery, particularly those with multiple comorbid health conditions.

**Pregnancy after breast cancer**

There are few data to guide the optimal timing of pregnancy after breast cancer, and this is an important area of ongoing research. Given the known benefits of adjuvant endocrine therapy, panelists generally favored an approach that involved 18–24 months of treatment with endocrine before pregnancy, and reiterated the importance of resuming endocrine treatment after pregnancy.

**Male breast cancer**

The vast majority of male breast cancers are ER positive. The Panel recommended that men with ER positive tumors should receive adjuvant tamoxifen. For men with true contraindications to tamoxifen, the Panel believed GnRH agonist therapy and an AI could be an alternative.

**Testing for hereditary breast cancer**

The Panel endorsed genetic testing of BRCA1 and BRCA2 for patients with strong family history of breast cancer regardless of age; for women diagnosed at age ≤40 years regardless of tumor subtype, or for women with triple-negative breast cancer age ≤60 years. Germline multigene panel testing may be offered to patients who meet criteria for hereditary cancer syndromes, including breast and ovarian or Lynch syndrome; and is particularly appropriate in cases of early-onset breast cancer or in women with strong family history of breast cancer when BRCA1/2 testing has been uninformative.

**Discussion**

**Conclusions**

The conference endorsed recent trial evidence supporting areas of ‘escalation’ or ‘de-escalation’ of local and systemic therapies. A large number of treatment recommendations are shown although a significant variation in the level of agreement was noted. In fact, among more than 200 questions, only a few statements...
(radiation in 4 or more positive nodes, distinction between luminal A- and luminal B-like in order to identify important clinical categories) resulted in 100% concordance. The large variation in the degrees of support is reflected in the votes recorded in supplementary Appendix S1, available at *Annals of Oncology* online. The Panel recognized that recommendations are not intended for all patients, but rather for the majority of them in common clinical situations. Fine-tuning of adjuvant therapies for the patient of today implies that the available treatments need to be adjusted to the patient’s tumor characteristics, co-morbidities, economic constraints and acceptance of therapies.

**Acknowledgements**

We gratefully thank all participants of the 15th St. Gallen International Breast Cancer Conference for their many useful suggestions. In addition to Panel members, we also thank Carmen Criscitiello, European Institute of Oncology, Milano and Michael Knauer, Kantonsspital, St. Gallen, for their substantial assistance in the collection of voting results. In recognition of their outstanding contribution as longstanding co-authors of several former St. Gallen consensus manuscripts, we especially want to thank Aron Goldhirsch, Alan Coates and Richard Gelber for their legacy and for their fundamental support of the conference-development and its consensus manuscript during the last 30 years.

**Funding**

None declared.

**Disclosure**

Conflict of interest statements from all presenters and Panel members were available on-line during the conference and are listed in supplementary Appendix S1, available at *Annals of Oncology* online.

**References**


67. Tolaney SM, Barry WT, Dang CT et al. Adjuvant paclitaxel and trastuzumab (T disc) v docetaxel (D disc) – advanced breast cancer (PaTrA). J Clin Oncol 2016; 34; (suppl; abstr 3530).


79. Urruticochea A, Rizwanullah M, Im SA et al. PHEREXA: a phase III study of trastuzumab (H) + capcitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting. J Clin Oncol 2016; 34; (suppl); abstr 504.


82. Tutt A, Ellis P, Kilburn L et al. TNT: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). In San Antonio Breast Cancer Symposium 2014, 9–13 December 2014, San Antonio, TX (abstr S3-01).

83. Diéras V, Han HS, Robson ME et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc) +/− C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. In: San Antonio Breast Cancer Symposium 2016, 6–10 December 2016, San Antonio, TX (abstr P4-22-02).


